The historical rank and industry rank for VYNE Therapeutics's Days Payable or its related term are showing as below:
During the past 11 years, VYNE Therapeutics's highest Days Payable was 1121.09. The lowest was 1121.09. And the median was 1121.09.
VYNE's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56 * Ranked among companies with meaningful Days Payable only.
VYNE Therapeutics's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
VYNE Therapeutics Days Payable Related Terms
VYNE Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for VYNE Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VYNE Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VYNE Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
VYNE Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics (VYNE) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on VYNE Therapeutics and its competitors. Over the past decade, VYNE Therapeutics' Days Payable has ranged from 1,121.09 to 1,121.09. According to the industry distribution chart, VYNE Therapeutics ranks #999999 out of 702 companies in the Biotechnology industry.
Is VYNE Therapeutics' Days Payable too high?
VYNE Therapeutics' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,121.09 to a high of 1,121.09. Based on the distribution chart, VYNE Therapeutics ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VYNE Therapeutics has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does VYNE Therapeutics' Days Payable compare to PLUR and MRKR?
According to the Biotechnology industry distribution chart, VYNE Therapeutics ranks #999999 out of 702 companies for Days Payable. This places VYNE Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. Historically, VYNE Therapeutics' own Days Payable has ranged from 1,121.09 to 1,121.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on VYNE Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VYNE Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VYNE Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, VYNE Therapeutics (VYNE) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.56, compared to a current price of $0.68 — trading 21.4% above its estimated fair value. The current Days Payable is 0.00. VYNE Therapeutics' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For VYNE Therapeutics (VYNE), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VYNE Therapeutics (VYNE) Overvalued in 2026?
Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued.
The current stock price of $0.68 is trading 21.4% above its estimated GF Value™ of $0.56.
GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.
Key valuation signals for VYNE:
Days Payable: 0.00
GF Value™: $0.56 vs. price of $0.68 (21.4% above fair value)
No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score
Get the complete analysis for VYNE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYNE has been successfully added to your 
